Japan’s TransGenic Dropping Knockout Mice For Antibodies
This article was originally published in PharmAsia News
Executive Summary
Instead of its usual practice of concentrating on creating mice with specific genetic defects, Japan's TransGenic is changing to focus more on diagnostics and reagent antibodies. The firm has decided "knockout mice" are too expensive to develop when new technologies are available so it has switched gears and plans instead to focus on licensing marketing rights for its antibodies. Prospective buyers would be makers of diagnostic drugs and reagents. Transgenic's plan is to make its antibody business a greater sales producer than its knockout mice. (Click here for more - a subscription may be required